Dr Paul Eliadis AM has been awarded the 2022 QAGOMA Medal for his exceptional and inspiring contribution to the Collection. Dr Eliadis was acknowledged for his outstanding generosity and commitment to supporting the arts in Queensland.
Dr Paul Eliadis, Haematologist and co-founder of Icon Cancer Centre, has been awarded an honorary doctorate in 2021 from the University of Queensland. The award of Doctor of Letters honoris causa recognises the impact that Dr Eliadis has had at the University, in the state and in the country, both through his leading medical career and his commitment to promoting the arts. “Universities are very special… Read More »Doctor of Letters honoris causa
“Universities are very special institutions that need to be devoted to learning, not just turning people out for jobs. As a society, that is something we must afford.” Dr Paul Eliadis AM Dr Paul Eliadis AM is a proud member of the UQ alumni. Throughout his professional life he has remained connected with The University of Queensland. Dr Eliadis AM is a benefactor of UQ’s… Read More »Dr Paul Eliadis AM – UQ Alumni
Dr Paul Eliadis AM established The Paul Eliadis Foundation to continue his support and commitment to the classics and ancient history. In this article we will be learning more about the Paul Eliadis Foundation, what it is and how it helps to preserve the studies of ancient history and the classics. What Is The Paul Eliadis Foundation The Eliadis Foundation is a private ancillary fund… Read More »The Paul Eliadis Foundation
Phase III study investigating Ibrutinub and Venetoclax for the treatment of patients with relapsed/refractory mantle cell lymphoma.
Dr Paul Eliadis AM was recently involved in a global Phase III study investigating Ibrutinub and Venetoclax for the treatment of patients with relapsed/refractory mantle cell lymphoma. You can read the full study and results by clicking here. On the study, Dr Eliadis AM noted: “It is always a privilege to work alongside my colleagues across the globe to help improve treatment approaches for patients… Read More »Phase III study investigating Ibrutinub and Venetoclax for the treatment of patients with relapsed/refractory mantle cell lymphoma.
Dr Paul Eliadis AM is the Co-Founder of Icon Group, Australia’s largest private provider of oncology clinical trials. Last month on International Clinical Trials Day, Icon Group released their first Annual Research Report. This is a fascinating report that details even through the Covid-19 pandemic, Icon Group’s research portfolio continued to grow. Throughout 2020, Icon Group saw record trial recruitment, increased tele-trials and the publication of milestone… Read More »Icon Group – Annual Research Report
The Emeritus Professor RD Milns AM Memorial Undergraduate Scholarship was established by the Friends of Antiquity and Alumni Friends Society in 2020 with the intent to support undergraduate Classics and Ancient History students who are facing financial hardship. As someone dedicated to the exploration and preservation of the classics and ancient history, Dr Paul Eliadis AM is a proud donor to the Emeritus Professor RD… Read More »The Emeritus Professor RD Milns AM Memorial Undergraduate Scholarship
Dr Paul Eliadis, Haematologist and co-founder of Icon Cancer Centre, has been honoured with a Member of the Order of Australia (AM). This was awarded for Dr Eliadis’ significant service to both the medical profession as a Haematologist and his charitable initiatives. “When I see a good opportunity I go for it. I’ve spent my life in medicine and arts, disciplines that I believe go… Read More »Dr Paul Eliadis appointed a Member of the Order of Australia